Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C568S303000, C514S749000
Reexamination Certificate
active
07910573
ABSTRACT:
The present invention relates to crystalline forms of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one. The invention relates in particular to two crystalline ansolvate/anhydrate forms of this compound, polymorphs I and II. However, the present invention also relates to crystalline solvates, for example methanol and ethanol solvates of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one as precursors for preparing these two polymorphs I and II. Processes for preparing polymorph I by displacement crystallization or by trituration are described. Selection of the last solvent before formation of the ansolvate can be based on the differences in the purification behaviour of the individual solvates of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one. Polymorph I according to the invention is particularly suitable for the manufacture of medicinal products.
REFERENCES:
patent: 4921846 (1990-05-01), Nedelec et al.
patent: 4954490 (1990-09-01), Cook et al.
patent: 5073548 (1991-12-01), Cook et al.
patent: 5108996 (1992-04-01), Claussner et al.
patent: 5407928 (1995-04-01), Kasch et al.
patent: 5739125 (1998-04-01), Kasch et al.
patent: 6020328 (2000-02-01), Cook et al.
patent: 6316432 (2001-11-01), Schwede et al.
patent: 6476079 (2002-11-01), Jukarainen et al.
patent: 6503895 (2003-01-01), Schwede et al.
patent: 6806263 (2004-10-01), Schwede et al.
patent: 6825182 (2004-11-01), Ring et al.
patent: 6861415 (2005-03-01), Kim et al.
patent: 7087591 (2006-08-01), Kim et al.
patent: 7148213 (2006-12-01), Schwede et al.
patent: 2004/0006241 (2004-01-01), Grawe et al.
patent: 2004/0157811 (2004-08-01), Lichtner et al.
patent: 2005/0080060 (2005-04-01), Schwede et al.
patent: 2005/0277769 (2005-12-01), Burton et al.
patent: 2007/0105828 (2007-05-01), Joshi et al.
patent: 19706061 (1998-08-01), None
patent: 10221034 (2003-11-01), None
patent: 0 411 733 (1991-02-01), None
patent: 0 676 203 (1995-10-01), None
patent: 0970103 (2000-01-01), None
patent: 0970103 (2002-04-01), None
patent: 978/MUM/2005 (2005-08-01), None
patent: 11171774 (1999-06-01), None
patent: WO-98/26783 (1998-06-01), None
patent: WO-98/34947 (1998-08-01), None
patent: WO 98/34947 (1998-08-01), None
patent: WO-99/53924 (1999-10-01), None
patent: WO-2006 010097 (2006-01-01), None
Caira, Topics in Current Chemistry (1988) 198:163-208).
Vippagunta et. al., Advanced Drug Delivery Reviews (2001) 48:3-26).
Davey (Current topics in crystallization process (1982) 8:429-479).
Ulrike Fuhrmann, et al.; “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist”; J. Med. Chem.; 2000; pp. 5010-5016; 43; American Chemical Society.
Walter Cabri, et al.; “Polymorphisms and Patent, Market and Legal Battles: Cefdinir Case Study”; Organic Process Research and Development; 2007; pp. 64-72; vol. 11, No. 1; American Chemical Society.
M. Bohl, et al.; “Molecular mechanics and X-ray crystal structure investigations on conformations of 11β substituted 4,9-dien-3-one steroids”; J. Mol. Graphics; Sep. 1989; pp. 122-153; vol. 7; Butterworth Publishers.
Dario Braga, et al.; “Crystal Polymorphism: Challenges at the Crossroads of Science and Technology”; Making Crystals by Design; pp. 293-314; 2007; Wiley-VCH Verlag GmbH & Co. KGaA.
David K. Tellekson, et al.; “Strategies for Attacking and Defending Pharmaceutical Patents . . .”; Intellectual Property & Technology Law Journal; Dec. 2005; pp. 5-14; vol. 17, No. 12; Aspen Publishers, Inc.
English translation of Office Action/Minutes; EP 06 090 095.8; dated Jan. 16, 2007; with attached extended European search report.
Maibauer R., et al.; “First human data for ZK 230211 (ZK-PRA), a new progesterone receptor . . .”; Abstracts-Poster Session IV, #4074; with attached poster, dated Dec. 14, 2006.
Ulrike Fuhrmann, et al.; “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist”; Journal of Medicinal Chemistry; 2000; pp. 5010-5016; vol. 43, No. 26; American Chemical Society.
Fuhrmann U, et al.; “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist”; J. Med. Chem.; 2000; pp. 5010-5016; Bd.43 Nr.26; American Chemical Society, XP001064233.
Bohl, M. et al., “Molecular mechanics and X-reay crystal structure investigations on conformations of 11β substituted 4,9-dien-3-one steroids,” J. Mol. Graphics, Sep. 1989, vol. 7.
Braga, Dario et al., “Crystal Polymorphism: Challenges at the Crossroads of Science and Technology,” Making Crystals by Design, 2007, pp. 293-314.
Cabri, Walter et al., “Polymorphisms and Patent, Market, and Legal Battles: Cefdinir Case Study,” Organic Process Research & Development, 2007, vol. 11, No. 1, pp. 64-72.
Caira, Mino R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 1998, vol. 198.
Priority Document for Indian Patent Application No. 978/MUM/2005 filed on Aug. 19, 2005.
Davey, R. J., “Solvent effects in crystallization processes,” Current Topics in Materials Science, 1982, vol. 8, pp. 429-479.
English Translation of Office Action for European Application No. 06 090 095 dated Jan. 16, 2007.
Fuhrmann, Ulrike et al., “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist,” J. Med. Chem, 2000, vol. 43, pp. 5010-5016.
Hazra, Braja G. et al., “Mifepristone (RU-486), the recently developed antiprogesterone drug and its analogues,” J. Indian Inst. Sci. May —Jun. 2001, vol. 81, pp. 287-298.
Kyowa Hakko Kogyo Co Ltd., “Agent for increasing hemocyte corpuscle,” Patent Abstracts of Japan, Publication Date: Jun. 29, 1999; English Abstracts of JP-11-171774.
Maibauer R. et al., “First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonists: a phase 1 clinical analysis of safety and pharmacokinetics in healthy postmenopausal women,” Abstracts-Poster Session IV, 2006.
Tellekson, David K. et al., “Strategies for Attacking and Defending Pharmaceutical Patents: A Modern Take on ‘The Art of War’,” 2005, vol. 17, No. 12, pp. 5-14.
Thomson Innovation Patent Record View, English Translation of Description and Claims retrieved on Aug. 20, 2010; English Abstract of EP0411733.
Thomson Innovation Patent Record View, English Translation of Description and Claims retrieved on Aug. 20, 2010; English Abstract of EP0676203.
Thomson Innovation Patent Record View, English Translation of Description and Claims retrieved on Aug. 20, 2010; English Abstract of WO98/026783.
Thomas Innovation Patent Record View, English Translation of Description and Claims retrieved on Aug. 20, 2010; English Abstract of WO99/053924.
Van Geerstein, J. V. et al., “Structure of the n-Butyl Acetate Solvate of 11β[4-(Dimethylamino)phenyl]-17β, hydroxy-17βhydroxy-17α-(1-propynyl)estra-4,9-dien-3-one,” Acta. Cryst., C42, 1986, pp. 1521-1523.
Vippagunta, Sudha R. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
Amoulong Evelin
Beckmann Wolfgang
Cleve Arwed
Ginko Thomas
Kraemer Edda
Bayer Schering Pharma AG
Fetterolf Brandon J
Millen White Zelano & Branigan P.C.
Sznaidman Marcos
LandOfFree
Crystalline forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675665